SAN CARLOS, Calif.--February 20, 2025--CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral, rapid onset, small molecule drugs to treat psychiatric and neurodegenerative diseases, announced today that it has treated its first subject with CuraAX, an alpha-1A adrenoceptor agonist, in a Phase 1 clinical trial. The company is developing CuraAX for patients with neurogenic orthostatic hypotension (nOH). Neurogenic orthostatic hypotension is a condition characterized by a significant, sudden drop in blood pressure upon standing, resulting in debilitating dizziness, fainting and cognitive impairment, due to inadequate blood flow to the brain. CuraAX is also expected to benefit cognition in patients with a range of neurologic conditions.
CuraSen Therapeutics Announces First Subject Treated with CuraAX (CST-3056) in a Phase 1 Clinical Trial
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
DURHAM, N.C. & SEATTLE--January 12, 2025--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution Foundation. The funding will accelerate the development of the company’s existing pipeline, currently anchored by Tune-401 – its clinical-stage epigenetic silencing drug for chronic Hepatitis B (HBV). It will also support the development of additional gene, cell, and regenerative therapy programs already underway at Tune, and to progress its broader mission of bringing the power and versatility of epigenetic therapies to bear on common and chronic diseases.
Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis
SALT LAKE CITY--(December 19, 2024)--Sorriso Pharmaceuticals, a biopharmaceutical company developing novel orally dosed antibodies for immune-mediated disease, today announced positive results from its Phase 1b clinical trial evaluating SOR102, an oral, dual-acting biologic targeting TNFα and IL-23, in patients with ulcerative colitis (UC). The study met its primary objectives, demonstrating a favorable safety and tolerability profile. Additionally, key exploratory efficacy endpoints showed promising activity of SOR102 across multiple clinical endpoints. This is the first successful demonstration of an orally dosed antibody delivering clinical efficacy.
Minoryx's leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy
Barcelona, Spain and Düsseldorf, Germany – 11 December 2024 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders and Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of CNS disorders, today announced that the NEXUS trial has been completed and that the primary endpoint has been met. The parties intend to file for European Marketing Authorization of leriglitazone in pediatric and adult cerebral Adrenoleukodystrophy (cALD) patients by mid-2025.
EarthOptics Secures $24 Million in Financing to Drive Expansion and Revolutionize Soil Digitization
ARLINGTON, Va., Nov. 19, 2024 -- EarthOptics, the industry leader in soil digitization and Predictive Agronomy, has announced the successful completion of $24 million in financing. This capital raise includes new partners Cibus Capital, RuralWorks Partners and Norinchukin Bank and is led by current investors Conti Ventures and The Production Board, with notable participation from Leaps by Bayer, S2G Ventures, Middleland Capital’s VTC Ventures, Cooperative Ventures, iSelect Fund, Serra Ventures, TO VC, Route 66 Ventures, Shell Ventures, Pappas Capital, CNH Ventures, and Rabo Ventures.
This investment underscores EarthOptics' unwavering commitment to advancing soil intelligence and enabling farmers, ranchers, and their advisors to make data-driven decisions that maximize profitability and sustainability. The funds will be deployed to accelerate technological innovation, broaden the company's geographic reach, and solidify its position as the authoritative source for soil insights.
AASLD 2024: Tune Therapeutics Shows Near-Complete HepB Virus Repression with Tune-401 Epigenetic Silencer
DURHAM, N.C. & SEATTLE--November 19, 2024--Leading epigenome editing company Tune Therapeutics showcased new data yesterday at the American Association for the Study of Liver Diseases (AASLD) conference, in support of its drive to develop a lasting, functional cure for chronic Hepatitis B Virus (HBV).
Tune unveiled its lead HBV program at the 2023 AASLD event with preclinical data showing strong and durable effect in targeted human hepatocytes. This year, Tune Therapeutics Principal Scientist Brian Cosgrove shared new in vitro and in vivo data, showcasing Tune’s clinically optimized liver-targeting LNP-RNA epi-silencing drug (Tune-401) – which enabled the near-complete repression of HBV RNA in human cells, and in a ‘true infection’ FRG mouse model.
Tune Therapeutics Moves into Clinical Spotlight with TUNE-401: A First-in-Class Epigenetic Silencer for Hepatitis B
DURHAM, N.C. & SEATTLE--November 14, 2024--Leading epigenome editing company Tune Therapeutics announced today that it has received clinical trial application (CTA) approval from the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) to initiate a Phase 1b clinical trial for TUNE-401 – an investigational epigenetic silencing therapy designed to treat chronic Hepatitis B (HBV). With this approval, TUNE-401 is expected to be the first epigenetic therapy to enter the clinic for the treatment of a common and infectious disease.
Aura Biosciences Reports Multiple Clinical Complete Responses Demonstrated in Ongoing Phase 1 Trial
BOSTON, Oct. 17, 2024 -- Aura Biosciences, Inc. (NASDAQ: AURA), today announced positive early data from an ongoing Phase 1 clinical trial of bel-sar (AU-011) in patients with NMIBC. To date, the trial includes 13 patients, with the primary endpoints of evaluating the safety and feasibility of local administration of bel-sar alone (n=5) and bel-sar with light activation (n=8). The secondary endpoints are to evaluate biological activity and immune mediated changes in the tumor microenvironment (TME). 10 of 13 study participants had low grade disease, approximating the 70% incidence of this patient population among all NMIBC patients. The other 3 study participants had high grade disease. In patients receiving bel-sar with light activation (n=8), 4 out of 5 patients with low grade disease demonstrated a clinical complete response with no tumor cells remaining on histopathological evaluation. 2 out of 3 patients with high grade disease demonstrated visual tumor shrinkage observed on cystoscopy.
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362
SAN DIEGO and PHILADELPHIA, Sept. 23, 2024 -- BioAtla, Inc. (“BioAtla”) (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (“CAB”) antibody therapeutics for the treatment of solid tumors, and Context Therapeutics Inc. (“Context”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the companies have entered into an agreement under which Context has obtained from BioAtla an exclusive, worldwide license to develop, manufacture and commercialize BA3362, BioAtla’s Nectin-4 x CD3 TCE. Context will assume and fund all development and commercialization activities.
Glycomine Receives FDA Fast Track Designation for GLM101 for the Treatment of PMM2-CDG
SAN CARLOS, Calif.--September 18, 2024--Glycomine, Inc., a biotechnology company focused on developing new therapies for orphan diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for GLM101, a mannose-1-phosphate replacement therapy in development for the treatment of patients with phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG).
